
New York Times
Glaxo undeterred by Human Genome 'poison pill'Boston.comLONDON—GlaxoSmithKline says it will persist with its bid to take over US company Human Genome Sciences despite the target's new `poison pill' defense. In a statement issued after the market closed on Thursday, GSK said it believes its $13 per share
...GlaxoSmithKline target adopts 'poison pill'Philadelphia Inquirer
all 261 news articles »